



ADA 2017: Conference At-a-glance

The American Diabetes Association Annual Meeting (Jun 9-13, 2017) released 1,355 scientific abstracts. Here's a quick snapshot.

Top Themes*

Clinical Trial Results

Themes	# Abstracts
Care Management / Retrospective Visits	86
Continuous Glucose Monitoring / Sensors	64
Liver / Nonalcoholic Fatty Liver Disease	55
Pregnancy / Gestational Diabetes	54
Weight Loss / Physical Activity	52
Hazard / Insurance	51
Homeostatic Model Assessment (HOMA)	49
Islet Cells / Autoimmune	48
Glomular / Kidney Disease	47
Neuropathy	46

Phase	Title	Conclusion
III Novo-Nordisk	Insulin Degludec/Liraglutide (IDegLira) Is Efficacious and Safe in Patients with Type 2 Diabetes (T2D) with Normal, Mild, or Moderate Renal Impairment: Analyses from Phase 3 Trials	<i>"IDegLira is safe and more efficacious than comparators in patients with mild or moderate renal impairment. The results resemble those observed in patients with normal renal function"</i>
III Mitsub Tanabe	Combination Therapy of Canagliflozin and Tenueligliptin in Japanese Patients with T2DM: Results from Phase 3 Studies	<i>"The combination of CAN and TNL is effective and well-tolerated in Japanese patients with T2DM"</i>
II Astra Zeneca	Safety Update on Dapagliflozin (DAPA) across the Phase 2b/3 Clinical Trial Program	<i>"DAPA was well tolerated across the clinical trial program. AE rates were generally balanced for DAPA vs. PBO/Control"</i>
II Eli Lilly	Results of a Phase 2 Study of the Oxyntomodulin (OXM) Analogue LY2944876 in Patients with Type 2 Diabetes (T2DM)	<i>"LY (30 and 50 mg) provides similar HbA1c lowering to ER with greater BW reduction and somewhat greater rates of GI events"</i>
II Novo Nordisk	The Effect of NNC0090-2746, a Dual GIP/GLP-1 Receptor Agonist (RA), on Glycemic Control, Plasma Cholesterol, and Body Weight in Subjects with Type 2 Diabetes: A Phase 2a Randomized Clinical Trial	<i>"NNC0090-2746 treatment improved glycemic control, reduced body weight and lowered total cholesterol, compared with placebo"</i>
II VtV Thx	TP273, Oral (Nonpeptide) GLP-1R Agonist: Improved Glycemic Control without Nausea and Vomiting in Phase 2	<i>"TTP273, oral GLP-1R agonist, can be efficacious without the side effects of nausea and vomiting"</i>

* Segmented abstracts into clusters based on common language